Head to Head Contrast: Metagenomi (NASDAQ:MGX) & Ernexa Therapeutics (NASDAQ:ERNA)

Ernexa Therapeutics (NASDAQ:ERNA) and Metagenomi (NASDAQ:MGX) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Ernexa Therapeutics and Metagenomi, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1	1	1	0	2.00
Metagenomi	1	0	2	1	2.75

Ernexa Therapeutics presently has a consensus price target of $30.00, suggesting a potential upside of 1,321.80%. Metagenomi has a consensus price target of $6.00, suggesting a potential upside of 596.70%. Given Ernexa Therapeutics’ higher possible upside, research analysts clearly believe Ernexa Therapeutics is more favorable than Metagenomi.

Insider and Institutional Ownership

70.6% of Ernexa Therapeutics shares are held by institutional investors. 0.5% of Ernexa Therapeutics shares are held by insiders. Comparatively, 12.5% of Metagenomi shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

Ernexa Therapeutics has a beta of 2.63, indicating that its share price is 163% more volatile than the S&P 500. Comparatively, Metagenomi has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500.

Valuation and Earnings

This table compares Ernexa Therapeutics and Metagenomi”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580,000.00	5.93	-$14.08 million	($14.35)	-0.15
Metagenomi	$25.21 million	1.29	-$87.87 million	($2.49)	-0.35

Ernexa Therapeutics has higher earnings, but lower revenue than Metagenomi. Metagenomi is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Ernexa Therapeutics and Metagenomi’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-305.93%	-169.86%
Metagenomi	-384.61%	-63.65%	-44.52%

Summary

Metagenomi beats Ernexa Therapeutics on 8 of the 14 factors compared between the two stocks.

About Ernexa Therapeutics

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

About Metagenomi

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.